Abstract
Johnson & Johnson (JNJ) stands as a titan in the healthcare conglomerate sector, having long played a significant role in the global market. This paper undertakes a literature review methodology to delve deeply into JNJ's historical context, diverse business arms, and financial prowess. A Discounted Cash Flow (DCF) and comparative valuation method are applied to assess JNJ's investment potential, supported by a rigorous risk evaluation encompassing various facets from market dynamics to legal challenges. Concurrently, the study gauges the alignment of JNJ's strategies with prevailing pharmaceutical and healthcare trends. Conclusively, the analysis suggests tailored investment recommendations, encapsulating both immediate and future outlooks. The primary objective is to furnish prospective investors with a well-rounded assessment of JNJ's investment promise.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
